Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2002

View Archived Issues

New data on the efficacy and safety of valdecoxib

ABI-007 trial cleared to continue

Novel antifungal compound SF-2822 described by Meiji Seika researchers

Sankyo patents new antibacterial agents isolated from Streptomyces cultures

Antifungal cyclic peptides prepared and tested at Takara Shuzo

Cell Therapeutics presents new inhibitors of IL-12 and IL-4 signaling for asthma, diabetes, etc.

New DPP-IV inhibitors in early development at Boehringer Ingelheim

Toyama presents novel agents with neuroprotective and neurotrophic activity

Banyu describes novel compounds able to increase GLP-1 levels

Keryx extends international manufacturing and negotiating rights for KRX-101

CollaGenex signs copromotion deal with Novartis for Denavir

Saegis licenses preclinical compound from Lilly for cognitive impairment

British Biotech and Serono extend antiinflammatory research agreement

First of three pivotal phase III trials of AC-2993 in type 2 diabetes completes enrollment

Inhibition of p38 MAP kinase associated with significant antiinflammatory effects in CIA

Two Genzyme enzyme replacement therapies up for FDA panel review in January

Pascolizumab characterized preclinically prior to clinical studies

Octapeptide based on alpha-MSH combines both antiinflammatory and antiinfective properties

Further development of LY-333531 for diabetic neuropathy and vasculopathy warranted

Potent and gut-selective Ca2+ channel antagonist with potential in IBS

GSK and Biosynexus to develop and commercialize staphylococcal antibodies and vaccines

Phase III Provenge trial resumes enrollment

Second Allox phase I/II trial completed

Chiron announces discontinuation of various programs

Cerebril phase II IND cleared

COGNIShunt system receives European regulatory approval

Statin induces apoptosis in RA synoviocytes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...